loader

BriaCell

TSX:BCT

Developing Personalized Off-The-Shelf Immunotherapy Treatments for Cancer Patients

Press Releases


Overview

BriaCell Therapeutics (NASDAQ:BCTX, BCTXW;TSX:BCT) is a clinical-phase biotechnology company developing innovative immunotherapies for treating cancer.

At the forefront of cancer treatments, immunotherapies boost the ability of the body's own cancer-fighting cells to destroy cancerous tumors. Immunotherapies also have low-toxicity, making it easier for patients to undergo treatment. Most importantly, they may offer better efficacy and less chance of recurrence for many cancer patients. A report released by Research and Markets says the global immuno-oncology market is expected to reach US$135 billion by 2024. BriaCell continues to uncover opportunities in this space with its innovative technologies.

Interactive Chart

×